Mi Deng

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, 100142, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 04, 2025

Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T.

Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T.

Journal: Antibody therapeutics

Published: November 18, 2025

Inhibition of Pax6 sumoylation suppresses the tumorigenicity of pancreatic cancer cells.

Inhibition of Pax6 sumoylation suppresses the tumorigenicity of pancreatic cancer cells.

Journal: Cell death and differentiation

Published: November 17, 2025

Eradicating measurable residual disease via immunotherapy to cure acute lymphoblastic leukemia: current status and future directions.

Eradicating measurable residual disease via immunotherapy to cure acute lymphoblastic leukemia: current status and future directions.

Journal: Expert review of clinical immunology

Published: August 21, 2025

The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and the risk of insulin resistance: results from the NHANES 2003-2016.

The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and the risk of insulin resistance: results from the NHANES 2003-2016.

Journal: BMC endocrine disorders

Published: March 21, 2025

In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy.

In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy.

Journal: Nature materials

Published: November 12, 2024

cGAMP promotes inner blood-retinal barrier breakdown through P2RX7-mediated transportation into microglia.

cGAMP promotes inner blood-retinal barrier breakdown through P2RX7-mediated transportation into microglia.

Journal: Journal of neuroinflammation

Published: October 18, 2024

Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging.

Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging.

Journal: Cell reports. Medicine

Published: October 10, 2024

Chidamide synergizes with cisplatin-etoposide to trigger pyroptosis and anti-tumor immunity in diffuse large B-cell lymphoma.

Chidamide synergizes with cisplatin-etoposide to trigger pyroptosis and anti-tumor immunity in diffuse large B-cell lymphoma.

Journal: Communications medicine

Published: October 09, 2024

Myeloid cells meet CD8+ T cell exhaustion in cancer: What, why and how.

Myeloid cells meet CD8+ T cell exhaustion in cancer: What, why and how.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: September 16, 2024

Interleukin-2-inducible T-cell kinase inhibition to block NF-κB signaling exerts anti-tumor effects and enhances chemotherapy in NK/T-cell lymphoma.

Interleukin-2-inducible T-cell kinase inhibition to block NF-κB signaling exerts anti-tumor effects and enhances chemotherapy in NK/T-cell lymphoma.

Journal: Cancer letters

Published: June 07, 2024

LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway.

LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 21, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026